LintonPharm announces authorization from China health authority (NMPA) to proceed with a phase 1/2 trial evaluating catumaxomab for the treatment of Non-Muscle Invasive Bladder Cancer
LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today announced that China’s health authority, …
..Indonesia was particularly concerned about recruitment practices that could constitute human trafficking.
Jakarta (ANTARA) - Indonesia urged Russia to halt...
LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today announced that China’s health authority, …